Accurate Education - Nutraceutical protocols: Inflammatory Bowel Diseases (IBD)

Nutraceutical protocols:

Inflammatory Bowel Diseases (IBD)

IBD encompasses Crohn’s disease (CD) and Ulcerative Colitis (UC), chronic relapsing-remitting inflammatory disorders affecting approximately 3 million adults in the United States.

See:

Nutraceutical Protocols:

Key to Links:

Grey text – handout
Red text – another page on this website
Blue text – Journal publication

Definitions and Terms Related to Pain

Nutraceutical protocols:

Inflammatory Bowel Diseases (IBD)

IBD encompasses Crohn’s disease (CD) and Ulcerative Colitis (UC), chronic relapsing-remitting inflammatory disorders.Pain in IBD is multifactorial, arising from active inflammation, visceral hypersensitivity, strictures, adhesions, and functional overlap (IBS-like symptoms in 20–50% of patients in remission).[3][4]

Conventional therapies (5-ASA, corticosteroids, immunosuppressants, biologics) carry significant adverse effects, driving patient interest in complementary approaches.[1][5] The 2024 AGA Clinical Practice Update emphasizes the importance of addressing nutritional deficiencies and recognizes emerging roles for dietary interventions.[6] the use of nutraceuticals offers multiple potential benefits for the various mechanisms that contribute to pain in eye IBD.

Pathophysiology Targeted:

Intestinal mucosal inflammation,
Epithelial barrier dysfunction
Gut microbiome dysbiosis
Oxidative stress
Immune dysregulation
NF-κB activation
Proinflammatory cytokine release (TNF-α, IL-1β, IL-6)
Visceral hypersensitivity,
Neuroinflammation
Micronutrient deficiencies

MECHANISTIC RATIONALE FOR NUTRACEUTICAL APPROACH

The pathophysiology of IBD involves several mechanisms targetable by nutraceuticals:

1. Intestinal inflammation: NF-κB activation, proinflammatory cytokine release. Curcumin, omega-3, Boswellia, and polyphenols inhibit NF-κB and reduce cytokine production.[7][8][9]

2. Epithelial barrier dysfunction: Tight junction disruption, increased permeability. PEA, omega-3, and vitamin D restore barrier integrity.[10][11][12]

3. Oxidative stress: Reactive oxygen species damage intestinal mucosa. Curcumin, resveratrol, quercetin, and ALA provide antioxidant protection.[13][8]

4. Gut microbiome dysbiosis: Altered bacterial composition perpetuates inflammation. Probiotics, prebiotics, and omega-3 modulate microbiome composition.[14][15]

5. Visceral hypersensitivity: Central and peripheral sensitization contribute to pain. PEA, melatonin, and magnesium address sensitization mechanisms.[Document][16]

6. Micronutrient deficiencies: Vitamin D, B12, iron, zinc, and folate deficiencies are common and perpetuate disease activity.[6][17]

—

NUTRACEUTICAL PROTOCOL FOR IBD

Tier 1: Core Agents (Strongest Evidence)

Agent	Dosing Protocol	Evidence Level	Mechanism/Rationale	References
Vitamin D3	25(OH)D Optimize to 40–60 ng/mL	Meta-analyses positive; AGA recommends	Reduces relapse risk; immune modulation; deficiency common in IBD; real-world data shows reduced ED visits/hospitalizations	[1], [2], [3], [4], [5]
Curcumin	1–3 gm daily (adjunct to 5-ASA)	RCTs positive for UC; AGA: no recommendation due to limited data	Induces clinical remission in UC; reduces hs-CRP, ESR; anti-inflammatory via NF-κB inhibition	[6], [7], [8], [9], [10]
Omega-3 (EPA/DHA)	2–4 gm daily	Mechanistic support; clinical trials mixed	Anti-inflammatory; increases SPMs (resolvins); modulates microbiome; reduces proinflammatory cytokines	[11], [12], [13], [14]
Probiotics	Multi-strain formulation (De Simone formulation for pouchitis)	AGA conditional recommendation for pouchitis prevention	Primary prevention and secondary prevention of pouchitis; limited evidence for active UC/CD	[15], [16], [17], [18]

[17][35][36][37][38] [39][40][41][42][43][44] [14][45][12][46] [47][15][48]

Vitamin D Evidence: A 2024 meta-analysis found vitamin D supplementation reduced clinical relapse risk (RR 0.64, 95% CI 0.46–0.89), with stronger effects in CD patients in remission (RR 0.47).[35] A 2023 Cochrane review found “there may be fewer clinical relapses when using vitamin D compared to placebo” (low certainty).[17] A 2025 real-world study of 5,021 IBD patients found vitamin D supplementation associated with 34% reduction in ED visits and 53% reduction in hospitalizations.[38]
Curcumin Evidence: A 2022 meta-analysis of 6 RCTs (385 participants) found adjuvant curcumin effective for inducing clinical remission in UC (RR 2.10, 95% CI 1.13–3.89).[40] An RCT of 1500 mg/day curcumin for 8 weeks showed significant improvement in clinical activity scores, quality of life, hs-CRP, and ESR compared to placebo.[42] The 2019 AGA guideline made no recommendation due to limited evidence but noted a trend toward benefit.[39]
Probiotics Evidence: The 2024 AGA Pouchitis Guideline conditionally recommends probiotics (De Simone formulation) for preventing recurrent pouchitis (low certainty evidence).[47] A 2025 meta-analysis found probiotics effective for primary (RR 0.18) and secondary prevention (RR 0.17) of pouchitis.[48] Evidence for active UC or CD is limited.[15]

—

Tier 2: Emerging Evidence Agents

Agent	Dosing Protocol	Evidence Level	Mechanism/Rationale	References
PEA (Palmitoylethanolamide)	600 mg 2x/day (ultramicronized)	Preclinical strong; limited clinical	Reduces colon inflammation via PPARα; improves epithelial barrier; prevents inflammation-induced hyperpermeability in human RCT	[1], [2], [3], [4]
Boswellia serrata	300–400 mg 3x/day (standardized extract)	Mixed clinical evidence	Anti-inflammatory via 5-LOX inhibition; preserves epithelial barrier; one RCT showed no benefit for CD maintenance	[5], [6], [7], [8]
Resveratrol	200–500 mg/day	Preclinical positive; limited clinical	Antioxidant; NF-κB inhibition; Reduces proinflammatory cytokines; Improves microbiome	[9]
Quercetin	500 mg 2x/day	Preclinical positive	Antioxidant; anti-inflammatory; Inhibits NF-κB; Reduces oxidative stress	[10]

[49][10][50][11] [51][9][52][53] [8] [7][8]

PEA Evidence: Preclinical studies demonstrate PEA improves colon inflammation through PPARα-dependent mechanisms, targeting the S100B/TLR4 axis on enteric glial cells.[10] A human RCT found PEA (and CBD) prevented aspirin-induced intestinal hyperpermeability, with implications for IBD.[11] NAAA inhibition (which increases endogenous PEA) reduced colon inflammation in murine colitis models.[49]
Boswellia Evidence: Boswellic acids inhibit 5-lipoxygenase and reduce leukotriene synthesis, with anti-inflammatory effects in IBD models.[9][54] However, a well-designed RCT of Boswellia extract (Boswelan) for CD maintenance showed no superiority over placebo, though safety was confirmed.[52] Earlier smaller studies suggested benefit in UC and collagenous colitis.[53]

—

Tier 3: Micronutrient Optimization

Agent	Dosing Protocol	Evidence Level	Rationale	References
Iron	IV preferred for active disease; oral for mild/remission	AGA recommends	Anemia common; IV more effective and better tolerated; dose based on hemoglobin and weight	[1]
Vitamin B12	Parenteral if ileal resection >30 cm	AGA recommends	Deficiency in 5.6–38% of CD; terminal ileum is primary absorption site	[1]
Folate	1 mg daily	Standard care	Deficiency common; may decrease with inflammation; important if on methotrexate	[1]
Zinc	25–50 mg daily if deficient	Supportive care	Deficiency associated with inflammation; may decrease with active disease	[1], [2]
Magnesium	400 mg daily	Supportive care	Deficiency possible with diarrhea; supports muscle function	[Document]

[6][6][55]

—

DISEASE-SPECIFIC PROTOCOLS

Ulcerative Colitis Protocol

Phase	Priority Nutraceuticals	Dosing	Rationale	References
Active UC	Curcumin (adjunct to 5-ASA)	1–3 gm daily	Induces clinical remission; reduces inflammatory markers	[1], [2], [3]
	Omega-3	2–4 gm daily	Anti-inflammatory; SPM production	[4]
	Vitamin D3	Optimize to 40–60 ng/mL	Immune modulation	[5]
UC Remission	Curcumin (maintenance)	1–2 g daily	Maintains remission at 6 months in one RCT)	[6]
	Vitamin D3	Maintain 40–60 ng/mL	Reduces relapse risk	[5]
	Probiotics	Multi-strain	May help maintain remission (limited evidence)	[7]
Pouchitis	Probiotics (De Simone formulation)	As directed	AGA conditional recommendation for prevention	[8]

[39][40][41][42][43][44][17][47]

Crohn’s Disease Protocol

Phase	Priority Nutraceuticals	Dosing	Rationale	References
Active CD	Vitamin D3	Optimize to 40–60 ng/mL	Immune modulation; reduces disease activity	[1], [2]
	Omega-3	2–4 g daily	Anti-inflammatory	[3]
	PEA	600 mg BID	Reduces neurogenic inflammation; visceral pain	[4]
CD Remission	Vitamin D3	Maintain 40–60 ng/mL	Strong evidence for relapse prevention	[1]
	Curcumin	1–2 g daily	Limited evidence; may help maintain remission	[5]
	B12	Parenteral if ileal involvement/resection	Prevent deficiency	[6]
Stricturing CD	Omega-3	2–4 g daily	Anti-inflammatory; may reduce fibrosis	[3]
	Curcumin	1–2 g daily	Anti-fibrotic properties (preclinical)	[5]

[17][35][14][10][44][6]

—

PAIN-SPECIFIC CONSIDERATIONS IN IBD

Pain in IBD is multifactorial and requires targeted approaches:

Pain Type	Characteristics	Nutraceutical Approach	References
Inflammatory pain	Active disease; correlates with biomarkers	Curcumin, Omega-3, Vitamin D (address underlying inflammation)	[1], [2], [3]
Visceral hypersensitivity	Pain despite remission; IBS-like	PEA, Melatonin, Magnesium (address sensitization)	[4], [5]
Stricture-related	Obstructive symptoms; postprandial	Limited nutraceutical role; may need intervention	[6]
Adhesion-related	Post-surgical; positional	Limited nutraceutical role	[6]
Functional overlap (IBS-IBD)	20–50% of IBD in remission	PEA, Probiotics, Low FODMAP diet	[7]

[39][40][14][10][16][4][3]

Functional GI Symptoms in IBD: The 2019 AGA Clinical Practice Update notes that 20–50% of IBD patients in remission experience IBS-like symptoms.[3] A Cochrane review found very low certainty evidence for most interventions for abdominal pain in IBD, with only transcranial direct current stimulation showing low-certainty benefit.[4] Nutraceuticals targeting visceral hypersensitivity (PEA, melatonin) may be helpful.

—

COMPREHENSIVE IBD PROTOCOL

Phase 1: Foundation (Weeks 1–4)

Goal: Address deficiencies; establish anti-inflammatory support

Vitamin D3: Check 25(OH)D; if <30 ng/mL, load with 50,000 IU weekly × 8 weeks; maintenance 2,000–5,000 IU daily to target 40–60 ng/mL
Omega-3: 2 g EPA+DHA daily
Iron: Check ferritin, transferrin saturation; supplement if deficient (IV preferred for active disease)
B12: Check levels; supplement if deficient (parenteral if ileal disease/resection)
Folate: 1 mg daily

Phase 2: Anti-Inflammatory Intensification (Weeks 4–8)

Goal: Add targeted anti-inflammatory agents

Continue Phase 1 agents
Add Curcumin: 1–2 g daily (UC) or 1 g daily (CD) as adjunct to standard therapy
Consider PEA: 600 mg BID if visceral pain/hypersensitivity present
Increase Omega-3 to 3–4 g daily if tolerated

Phase 3: Maintenance (Weeks 8+)

Goal: Sustain remission; prevent relapse

Continue effective agents
Vitamin D3: Maintain 40–60 ng/mL (recheck every 3–6 months)
Curcumin: 1–2 g daily for maintenance
Probiotics: Consider multi-strain formulation (especially for pouchitis prevention)
Melatonin: 3–5 mg QHS if sleep disruption or visceral hypersensitivity

—

INTEGRATION WITH STANDARD IBD THERAPY

Nutraceuticals should complement, not replace, evidence-based IBD treatments:

Standard Therapy	Nutraceutical Synergy	Considerations	References
5-ASA (mesalamine)	Curcumin (adjunct)	Best evidence for curcumin as add-on to 5-ASA in UC	[1], [2]
Corticosteroids	Vitamin D, Omega-3	Address steroid-induced bone loss; anti-inflammatory support	[3]
Immunomodulators (AZA, MTX)	Folate, B12, Vitamin D	Prevent deficiencies; MTX requires folate supplementation	[4]
Biologics (anti-TNF, vedolizumab)	Full protocol	Nutraceuticals target complementary pathways	[5]
Enteral nutrition	Omega-3, Vitamin D	Enteral nutrition effective for CD induction; nutraceuticals support	[6]

[39][40][6][2][56]

—

MONITORING AND ASSESSMENT

Expected Timeline:

Weeks 1–4: Vitamin D levels begin to rise; possible modest symptom improvement
Weeks 4–8: Curcumin effects may become apparent; inflammatory markers may improve
Weeks 8–12: Full assessment of efficacy; disease activity reassessment
Long-term: Sustained remission; reduced relapse risk with vitamin D optimization

—

SPECIAL CONSIDERATIONS

Pregnancy:

Vitamin D: Safe; optimize levels
Omega-3: Generally safe; may benefit fetal development
Curcumin: Limited safety data; use with caution
Probiotics: Generally considered safe

Pediatric IBD:

Exclusive enteral nutrition is first-line for CD induction in children[2]
Vitamin D optimization important
Curcumin: Limited pediatric data

Drug Interactions:

Curcumin: May inhibit CYP enzymes; potential interactions with immunosuppressants
Omega-3: May increase bleeding risk with anticoagulants
Vitamin D: Generally safe; monitor calcium levels with high doses

Dietary Considerations: The 2024 AGA Clinical Practice Update emphasizes dietary interventions alongside nutraceuticals:[6]

Mediterranean diet may be beneficial
Low FODMAP diet may help functional symptoms
Avoid ultra-processed foods and emulsifiers
Adequate fiber intake (when tolerated) supports SCFA production

—

PATIENT EDUCATION HANDOUT

Managing Inflammatory Bowel Disease: Your Supplement Guide

Understanding Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) includes Crohn’s disease and ulcerative colitis—chronic conditions that cause inflammation in your digestive tract. While medications are the cornerstone of treatment, certain supplements may help support your overall health and potentially reduce inflammation.

Many people with IBD are interested in natural approaches to complement their medical treatment. This guide explains which supplements have evidence to support their use and how to use them safely.

—

Important: Supplements Are Not a Replacement for Medication

Supplements should be used alongside—not instead of—your prescribed IBD medications. Always discuss any supplements with your gastroenterologist before starting them.

—

Supplements with Good Evidence

Vitamin D – Dose based on your blood level

– Many people with IBD have low vitamin D levels

– Research shows vitamin D may help reduce flare-ups

– Your doctor will check your level and recommend the right dose

– Goal is usually 40–60 ng/mL

– Safe and well-tolerated

Curcumin – 1–3 grams daily (for ulcerative colitis)

– The active ingredient in turmeric

– Studies show it may help achieve remission when added to standard medications

– Works best as an add-on to mesalamine (5-ASA)

– May reduce inflammation markers

– Generally well-tolerated; may cause mild stomach upset

Omega-3 Fish Oil – 2–4 grams daily

– Contains EPA and DHA, which have anti-inflammatory effects

– May help reduce inflammation in the gut

– Also good for heart and brain health

– Choose high-quality, purified fish oil

Probiotics – Multi-strain formulation

– May help prevent pouchitis (inflammation of the J-pouch after surgery)

– Evidence for active Crohn’s or ulcerative colitis is limited

– Generally safe with few side effects

– Different strains have different effects—ask your doctor which is best for you

—

Correcting Nutritional Deficiencies

IBD can cause deficiencies in several important nutrients. Your doctor may recommend:

Iron: If you have anemia (low red blood cells)

– IV iron is often preferred because it works faster and is better tolerated

– Oral iron can worsen stomach symptoms in some people

Vitamin B12: Especially if you have Crohn’s disease affecting the small intestine

– May need injections if you’ve had intestinal surgery

Folate: Important for cell health

– Especially important if you take methotrexate

Zinc: May be low during active inflammation

—

Supplements That May Help with Pain

If you have abdominal pain even when your IBD is in remission, these supplements may help:

PEA (Palmitoylethanolamide) – 600 mg twice daily

– A natural substance that reduces inflammation and pain

– May help with visceral (gut) pain

– Well-tolerated with few side effects

Melatonin – 3–5 mg at bedtime

– May help with pain and sleep

– Has anti-inflammatory properties

—

What to Expect

Supplements work gradually and should be part of a long-term plan:

– Weeks 1–4: Vitamin D levels begin to improve

– Weeks 4–8: You may notice some improvement in symptoms

– Weeks 8–12: Full assessment of whether supplements are helping

– Long-term: Continued use may help maintain remission

—

Safety Information

– Tell your gastroenterologist about all supplements you take

– Some supplements may interact with your medications

– Stop supplements if you notice any concerning side effects

– Curcumin may interact with blood thinners and some medications

– Fish oil may increase bleeding risk if you take blood thinners

When to Contact Your Healthcare Team:

– If your symptoms worsen

– If you develop new symptoms

– If you experience any side effects

– Before starting any new supplement

—

Working With Your Healthcare Team

The best approach to IBD combines:

– Medications prescribed by your gastroenterologist

– A healthy diet (Mediterranean-style eating may be beneficial)

– Supplements to correct deficiencies and support your health

– Regular monitoring with blood tests and colonoscopies

– Stress management and adequate sleep

Together with your healthcare team, you can find the best combination to manage your IBD and improve your quality of life.

—

Clinical Implementation Notes

The evidence for nutraceuticals in IBD varies considerably by agent and indication:

Vitamin D has the strongest evidence, with multiple meta-analyses demonstrating reduced relapse risk, particularly in CD patients in remission.[17][35][36] The 2024 AGA Clinical Practice Update emphasizes vitamin D optimization for all IBD patients.[6] A 2025 real-world study of over 5,000 IBD patients found vitamin D supplementation associated with significant reductions in ED visits, hospitalizations, and corticosteroid use.[38]

Curcumin has promising evidence for UC, with a 2022 meta-analysis showing efficacy for inducing clinical remission (RR 2.10).[40] However, the 2019 AGA guideline made no recommendation due to limited evidence and concerns about blinding in trials.[39] Curcumin should be used as an adjunct to 5-ASA, not as monotherapy.

Omega-3 fatty acids have strong mechanistic rationale and preclinical evidence, but clinical trials for relapse prevention have been disappointing.[12] The 2024 review notes that “international recommendations are supported that adequate diet-derived n-3 PUFAs might be beneficial in maintaining remission.”[12]

Probiotics have the strongest evidence for pouchitis prevention (De Simone formulation), with the 2024 AGA Pouchitis Guideline providing a conditional recommendation.[47] Evidence for active UC or CD is limited.[15]

PEA has strong preclinical evidence for reducing colon inflammation and improving epithelial barrier function.[10][50] A human RCT demonstrated PEA prevents inflammation-induced intestinal hyperpermeability.[11] Clinical trials specifically in IBD are needed.

Boswellia showed promise in early studies but a well-designed RCT for CD maintenance showed no benefit over placebo.[52] It may still have a role in UC or as adjunctive therapy, but evidence is limited.

Important caveats: The 2021 Cochrane review on interventions for abdominal pain in IBD found very low certainty evidence for most interventions, highlighting the need for better-designed trials.[4] Nutraceuticals should be viewed as complementary to standard IBD therapy, not as replacements. Patients should be counseled that evidence is strongest for vitamin D and curcumin (in UC), while other agents have more limited clinical data.

Would you like me to create a comprehensive summary document combining all eleven condition-specific protocols, or develop monitoring flowsheets and drug-nutraceutical interaction tables for clinical implementation?

References

Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn’s Disease and Ulcerative Colitis. Parian A, Limketkai BN. Current Pharmaceutical Design. 2016;22(2):180-8. doi:10.2174/1381612822666151112145033.
Nutritional Interventions in the Patient With Inflammatory Bowel Disease. Limketkai BN, Wolf A, Parian AM. Gastroenterology Clinics of North America. 2018;47(1):155-177. doi:10.1016/j.gtc.2017.09.007.
AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review. Colombel JF, Shin A, Gibson PR. Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association. 2019;17(3):380-390.e1. doi:10.1016/j.cgh.2018.08.001.
Interventions for the Management of Abdominal Pain in Crohn’s Disease and Inflammatory Bowel Disease. Sinopoulou V, Gordon M, Akobeng AK, et al. The Cochrane Database of Systematic Reviews. 2021;11:CD013531. doi:10.1002/14651858.CD013531.pub2.
The Significant Role of Nutraceutical Compounds in Ulcerative Colitis Treatment. Maio AC, Basile G, Iacopetta D, et al. Current Medicinal Chemistry. 2022;29(24):4216-4234. doi:10.2174/0929867329666211227121321.
AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review. Hashash JG, Elkins J, Lewis JD, Binion DG. Gastroenterology. 2024;166(3):521-532. doi:10.1053/j.gastro.2023.11.303.
Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease. Duan L, Cheng S, Li L, et al. Frontiers in Pharmacology. 2021;12:684486. doi:10.3389/fphar.2021.684486.
Polyphenols and Inflammatory Bowel Disease: Natural Products With Therapeutic Effects?. Vaghari-Tabari M, Alemi F, Zokaei M, et al. Critical Reviews in Food Science and Nutrition. 2024;64(13):4155-4178. doi:10.1080/10408398.2022.2139222.
Boswellic Acids and Their Role in Chronic Inflammatory Diseases. Ammon HP. Advances in Experimental Medicine and Biology. 2016;928:291-327. doi:10.1007/978-3-319-41334-1_13.
Palmitoylethanolamide Improves Colon Inflammation Through an Enteric Glia/Toll Like Receptor 4-Dependent PPAR-α Activation. Esposito G, Capoccia E, Turco F, et al. Gut. 2014;63(8):1300-12. doi:10.1136/gutjnl-2013-305005.
Palmitoylethanolamide and Cannabidiol Prevent Inflammation-Induced Hyperpermeability of the Human Gut in Vitro and in Vivo-a Randomized, Placebo-Controlled, Double-Blind Controlled Trial. Couch DG, Cook H, Ortori C, et al. Inflammatory Bowel Diseases. 2019;25(6):1006-1018. doi:10.1093/ibd/izz017.
Nutritional Lipids and Mucosal Inflammation. Wawrzyniak P, Noureddine N, Wawrzyniak M, et al. Molecular Nutrition & Food Research. 2021;65(5):e1901269. doi:10.1002/mnfr.201901269.
Diet Supporting Therapy for Inflammatory Bowel Diseases. Kikut J, Konecka N, Ziętek M, Kulpa D, Szczuko M. European Journal of Nutrition. 2021;60(5):2275-2291. doi:10.1007/s00394-021-02489-0.
A Potential Role for Gut Microbes in Mediating Effects of Omega-3 Fatty Acids in Inflammatory Bowel Diseases: A Comprehensive Review. Arjomand Fard N, Bording-Jorgensen M, Wine E. Current Microbiology. 2023;80(11):363. doi:10.1007/s00284-023-03482-y.
AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Su GL, Ko CW, Bercik P, et al. Gastroenterology. 2020;159(2):697-705. doi:10.1053/j.gastro.2020.05.059.
Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding. Viña I, López-Moreno M. Nutrition Reviews. 2025;83(7):e1604-e1618. doi:10.1093/nutrit/nuae203.
Vitamin D for the Treatment of Inflammatory Bowel Disease. Wallace C, Gordon M, Sinopoulou V, Limketkai BN. The Cochrane Database of Systematic Reviews. 2023;10:CD011806. doi:10.1002/14651858.CD011806.pub2.
Migraine. Dodick DW. Lancet (London, England). 2018;391(10127):1315-1330. doi:10.1016/S0140-6736(18)30478-1.
Glia Signaling and Brain Microenvironment in Migraine. Amani H, Soltani Khaboushan A, Terwindt GM, Tafakhori A. Molecular Neurobiology. 2023;60(7):3911-3934. doi:10.1007/s12035-023-03300-3.
Exploring the Epigenetic Modifications of the RONS-TRPA1-CGRP Axis in Migraine Pathophysiology. Fila M, Pawlowska E, Krekora J, Mitus-Kenig M, Blasiak J. The Journal of Headache and Pain. 2025;26(1):191. doi:10.1186/s10194-025-02114-z.
The Putative Role of Neuroinflammation in the Complex Pathophysiology of Migraine: From Bench to Bedside. Biscetti L, Cresta E, Cupini LM, Calabresi P, Sarchielli P. Neurobiology of Disease. 2023;180:106072. doi:10.1016/j.nbd.2023.106072.
Migraine. Ashina M. The New England Journal of Medicine. 2020;383(19):1866-1876. doi:10.1056/NEJMra1915327.
Effects of Selected Dietary Supplements on Migraine Prophylaxis: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials. Talandashti MK, Shahinfar H, Delgarm P, Jazayeri S. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2025;46(2):651-670. doi:10.1007/s10072-024-07794-0.
Non-Opioid Analgesics for the Prevention of Chronic Postsurgical Pain: A Systematic Review and Network Meta-Analysis. Doleman B, Mathiesen O, Sutton AJ, et al. British Journal of Anaesthesia. 2023;130(6):719-728. doi:10.1016/j.bja.2023.02.041.
Pharmacotherapy for the Prevention of Chronic Pain After Surgery in Adults: An Updated Systematic Review and Meta-Analysis. Carley ME, Chaparro LE, Choinière M, et al. Anesthesiology. 2021;135(2):304-325. doi:10.1097/ALN.0000000000003837.
Nutritional Intervention in Chronic Pain: An Innovative Way of Targeting Central Nervous System Sensitization?. Nijs J, Tumkaya Yilmaz S, Elma Ö, et al. Expert Opinion on Therapeutic Targets. 2020;24(8):793-803. doi:10.1080/14728222.2020.1784142.
Persistent Postsurgical Pain: Risk Factors and Prevention. Kehlet H, Jensen TS, Woolf CJ. Lancet (London, England). 2006;367(9522):1618-25. doi:10.1016/S0140-6736(06)68700-X.
Clinical Efficacy of Magnesium in Perioperative Pain Management: A Narrative Review. Ahmadzadeh S, Wentling JG, Ford BM, et al. Current Pain and Headache Reports. 2025;29(1):117. doi:10.1007/s11916-025-01422-y.
Perioperative Systemic Magnesium to Minimize Postoperative Pain: A Meta-Analysis of Randomized Controlled Trials. De Oliveira GS, Castro-Alves LJ, Khan JH, McCarthy RJ. Anesthesiology. 2013;119(1):178-90. doi:10.1097/ALN.0b013e318297630d.
Effects of Magnesium Sulfate Administration in Attenuating Chronic Postsurgical Pain in Rats. Kido K, Katagiri N, Kawana H, et al. Biochemical and Biophysical Research Communications. 2021;534:395-400. doi:10.1016/j.bbrc.2020.11.069.
Effect of Hypovitaminosis D on Postoperative Pain Outcomes and Short-Term Health-Related Quality of Life After Knee Arthroplasty: A Cohort Study. Lee A, Chan SKC, Samy W, Chiu CH, Gin T. Medicine. 2015;94(42):e1812. doi:10.1097/MD.0000000000001812.
Perioperative Serum 25-Hydroxyvitamin D Levels as a Predictor of Postoperative Opioid Use and Opioid Use Disorder: A Cohort Study. Kim Y, Zhang F, Su K, et al. Journal of General Internal Medicine. 2020;35(9):2545-2552. doi:10.1007/s11606-020-06001-y.
Ultramicronized N-Palmitoylethanolamine Associated With Analgesics: Effects Against Persistent Pain. Nobili S, Micheli L, Lucarini E, et al. Pharmacology & Therapeutics. 2024;258:108649. doi:10.1016/j.pharmthera.2024.108649.
Palmitoylethanolamide in the Treatment of Chronic Pain Caused by Different Etiopathogenesis. Gatti A, Lazzari M, Gianfelice V, et al. Pain Medicine (Malden, Mass.). 2012;13(9):1121-30. doi:10.1111/j.1526-4637.2012.01432.x.
Effectiveness of Vitamin D Supplementation on Disease Course in Inflammatory Bowel Disease Patients: Systematic Review With Meta-Analysis. Valvano M, Magistroni M, Cesaro N, et al. Inflammatory Bowel Diseases. 2024;30(2):281-291. doi:10.1093/ibd/izac253.
Vitamin D Therapy in Adults With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Guzman-Prado Y, Samson O, Segal JP, Limdi JK, Hayee B. Inflammatory Bowel Diseases. 2020;26(12):1819-1830. doi:10.1093/ibd/izaa087.
Efficacy of Vitamin D in Treatment of Inflammatory Bowel Disease: A Meta-Analysis. Li J, Chen N, Wang D, Zhang J, Gong X. Medicine. 2018;97(46):e12662. doi:10.1097/MD.0000000000012662.
The Real-World Impact of Vitamin D Supplementation on Inflammatory Bowel Disease Clinical Outcomes. Sninsky JA, Sansgiry S, Taylor T, et al. Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association. 2025;:S1542-3565(25)00624-X. doi:10.1016/j.cgh.2025.07.013.
AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. Ko CW, Singh S, Feuerstein JD, et al. Gastroenterology. 2019;156(3):748-764. doi:10.1053/j.gastro.2018.12.009.
Efficacy and Safety of Adjuvant Curcumin Therapy in Ulcerative Colitis: A Systematic Review and Meta-Analysis. Yin J, Wei L, Wang N, Li X, Miao M. Journal of Ethnopharmacology. 2022;289:115041. doi:10.1016/j.jep.2022.115041.
A Systematic Review of the Clinical Use of Curcumin for the Management of Gastrointestinal Diseases. Atefi M, Darand M, Entezari MH, et al. Advances in Experimental Medicine and Biology. 2021;1291:295-326. doi:10.1007/978-3-030-56153-6_18.
The Effect of Curcumin Supplementation on Clinical Outcomes and Inflammatory Markers in Patients With Ulcerative Colitis. Sadeghi N, Mansoori A, Shayesteh A, Hashemi SJ. Phytotherapy Research : PTR. 2020;34(5):1123-1133. doi:10.1002/ptr.6581.
Curcumin for Maintenance of Remission in Ulcerative Colitis. Kumar S, Ahuja V, Sankar MJ, Kumar A, Moss AC. The Cochrane Database of Systematic Reviews. 2012;10:CD008424. doi:10.1002/14651858.CD008424.pub2.
Effects of the Use of Curcumin on Ulcerative Colitis and Crohn’s Disease: A Systematic Review. Goulart RA, Barbalho SM, Lima VM, et al. Journal of Medicinal Food. 2021;24(7):675-685. doi:10.1089/jmf.2020.0129.
Fatty Acids and Lipid Mediators in Inflammatory Bowel Disease: From Mechanism to Treatment. Yan D, Ye S, He Y, et al. Frontiers in Immunology. 2023;14:1286667. doi:10.3389/fimmu.2023.1286667.
The Resolvin D2 and Omega-3 Polyunsaturated Fatty Acid as a New Possible Therapeutic Approach for Inflammatory Bowel Diseases. Chaim FHM, Pascoal LB, de Castro MM, et al. Scientific Reports. 2024;14(1):28698. doi:10.1038/s41598-024-80051-8.
AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders. Barnes EL, Agrawal M, Syal G, et al. Gastroenterology. 2024;166(1):59-85. doi:10.1053/j.gastro.2023.10.015.
Medical Therapies for Prevention and Treatment of Inflammatory Pouch Disorders-a Systematic Review and Meta-Analysis. Syal G, Barnes E, Raffals L, et al. The American Journal of Gastroenterology. 2025;120(1):135-150. doi:10.14309/ajg.0000000000003136.
N-Acylethanolamine-Hydrolyzing Acid Amidase Inhibition Increases Colon N-Palmitoylethanolamine Levels and Counteracts Murine Colitis. Alhouayek M, Bottemanne P, Subramanian KV, et al. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology. 2015;29(2):650-61. doi:10.1096/fj.14-255208.
Palmitoylethanolamide, a Naturally Occurring Lipid, Is an Orally Effective Intestinal Anti-Inflammatory Agent. Borrelli F, Romano B, Petrosino S, et al. British Journal of Pharmacology. 2015;172(1):142-58. doi:10.1111/bph.12907.
Boswellia Serrata Preserves Intestinal Epithelial Barrier From Oxidative and Inflammatory Damage. Catanzaro D, Rancan S, Orso G, et al. PloS One. 2015;10(5):e0125375. doi:10.1371/journal.pone.0125375.
Randomized, Placebo-Controlled, Double-Blind Trial of Boswellia Serrata in Maintaining Remission of Crohn’s Disease: Good Safety Profile but Lack of Efficacy. Holtmeier W, Zeuzem S, Preiss J, et al. Inflammatory Bowel Diseases. 2011;17(2):573-82. doi:10.1002/ibd.21345.
Frankincense: Systematic Review. Ernst E. BMJ (Clinical Research Ed.). 2008;337:a2813. doi:10.1136/bmj.a2813.
Modulation of the Immune System by Boswellia Serrata Extracts and Boswellic Acids. Ammon HP. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology. 2010;17(11):862-7. doi:10.1016/j.phymed.2010.03.003.
The Role of Dietary Supplements in Inflammatory Bowel Disease: A Systematic Review. Rossi RE, Whyand T, Murray CD, et al. European Journal of Gastroenterology & Hepatology. 2016;28(12):1357-1364. doi:10.1097/MEG.0000000000000728.
Dietary and Enteral Interventions for Crohn’s Disease. Yamamoto T, Shimoyama T, Kuriyama M. Current Opinion in Biotechnology. 2017;44:69-73. doi:10.1016/j.copbio.2016.11.011.

Emphasis on Education

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

Should you wish more information regarding any of the subjects listed – or not listed – here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

For more information, please contact Accurate Clinic.

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.